Daily Endocrinology Research Analysis
Three high-impact endocrinology-related studies stand out today: a phase 3 RCT shows the aldosterone synthase inhibitor baxdrostat significantly lowers systolic blood pressure in uncontrolled/resistant hypertension; a nationwide causal-inference cohort reveals that SGLT2 inhibitor cardiovascular benefits are heterogeneous and better predicted by individual traits rather than overall CVD risk; and a UK Biobank analysis uncovers that central obesity and diabetes elevate fracture risk despite highe
Summary
Three high-impact endocrinology-related studies stand out today: a phase 3 RCT shows the aldosterone synthase inhibitor baxdrostat significantly lowers systolic blood pressure in uncontrolled/resistant hypertension; a nationwide causal-inference cohort reveals that SGLT2 inhibitor cardiovascular benefits are heterogeneous and better predicted by individual traits rather than overall CVD risk; and a UK Biobank analysis uncovers that central obesity and diabetes elevate fracture risk despite higher BMI appearing protective.
Research Themes
- Aldosterone pathway inhibition for resistant hypertension
- Precision cardiometabolic therapy using heterogeneous treatment effect modeling
- Skeletal risk assessment beyond BMI: role of central adiposity and diabetes
Selected Articles
1. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.
In a phase 3, double-blind RCT of 794 patients with uncontrolled/resistant hypertension, baxdrostat 1 mg and 2 mg reduced seated systolic blood pressure by 8.7 and 9.8 mmHg more than placebo at 12 weeks. Hyperkalemia (>6.0 mmol/L) occurred infrequently (2.3%–3.0% vs 0.4% with placebo).
Impact: Introduces a first-in-class aldosterone synthase inhibitor demonstrating clinically meaningful BP reduction in hard-to-treat hypertension, potentially altering therapeutic algorithms.
Clinical Implications: Baxdrostat could become an add-on option for uncontrolled/resistant hypertension, especially in aldosterone-driven phenotypes, with routine potassium monitoring.
Key Findings
- Placebo-corrected seated SBP reduction at 12 weeks: −8.7 mmHg (1 mg) and −9.8 mmHg (2 mg), both P<0.001
- Hyperkalemia >6.0 mmol/L: 2.3% (1 mg), 3.0% (2 mg) vs 0.4% (placebo)
- Consistent BP lowering on top of multi-drug background therapy including a diuretic
Methodological Strengths
- Multinational, double-blind, randomized, placebo-controlled phase 3 design
- Adequate sample size with prespecified primary endpoint and consistent results across doses
Limitations
- Short duration (12 weeks) without cardiovascular outcome assessment
- Risk of hyperkalemia requires monitoring; applicability to severe CKD not established
Future Directions: Longer-term trials assessing cardiovascular outcomes, safety in CKD, and head-to-head comparisons with mineralocorticoid receptor antagonists.
BACKGROUND: Aldosterone dysregulation plays an important pathogenic role in hard-to-control hypertension. In several studies, baxdrostat, an aldosterone synthase inhibitor, reduced the seated systolic blood pressure of patients with uncontrolled or resistant hypertension. METHODS: In this phase 3, multinational, double-blind, randomized, placebo-controlled trial, we recruited patients with a seated systolic blood pressure of between 140 mm Hg and less than 170 mm Hg despite the receipt of stable treatment with two antihypertensive medications (uncontrolled hypertension) or three or more such medications (resistant hypertension), including a diuretic. After a 2-week placebo run-in period, we randomly assigned patients with a seated systolic blood pressure of 135 mm Hg or more in a 1:1:1 ratio to receive baxdrostat at a dose of 1 mg, baxdrostat at a dose of 2 mg, or placebo once daily for 12 weeks. The primary end point was the change in seated systolic blood pressure from baseline to week 12. RESULTS: A total of 796 patients underwent randomization and 794 received 1-mg baxdrostat (264 patients), 2-mg baxdrostat (266 patients), or placebo (264 patients) in addition to background therapy. At 12 weeks, the change from baseline in the least-squares mean seated systolic blood pressure was -14.5 mm Hg (95% confidence interval [CI], -16.5 to -12.5) with 1-mg baxdrostat, -15.7 mm Hg (95% CI, -17.6 to -13.7) with 2-mg baxdrostat, and -5.8 mm Hg (95% CI, -7.9 to -3.8) with placebo. The estimated difference from placebo (placebo-corrected difference) was -8.7 mm Hg (95% CI, -11.5 to -5.8) with 1-mg baxdrostat and -9.8 mm Hg (95% CI, -12.6 to -7.0) with 2-mg baxdrostat (P<0.001 for both comparisons). A potassium level of more than 6.0 mmol per liter was reported in 6 patients (2.3%) with 1-mg baxdrostat, in 8 patients (3.0%) with 2-mg baxdrostat, and in 1 patient (0.4%) with placebo. CONCLUSIONS: Among patients with uncontrolled or resistant hypertension, the addition of baxdrostat to background therapy resulted in a significantly lower seated systolic blood pressure at 12 weeks than placebo. (Funded by AstraZeneca and others; BaxHTN ClinicalTrials.gov number, NCT06034743.).
2. Heterogeneous Cardiovascular Effects of SGLT2 Inhibitors in Type 2 Diabetes: A Causal Forest and Target Trial Emulation Study.
In 150,830 working-age adults with T2D, SGLT2 inhibitors reduced a 3-year composite of death/MI/stroke/HF compared with DPP4 inhibitors, with an absolute risk reduction of about 0.38 percentage points. Treatment benefit was heterogeneous and better predicted by individual BP, BMI, and fasting glucose than by overall CVD risk.
Impact: Combines target trial emulation with causal forests at national scale to reveal individualized benefit signals for SGLT2i, guiding precision prescribing beyond conventional risk scores.
Clinical Implications: Consider SGLT2 inhibitors for broader T2D populations, including those with lower aggregate CVD risk but with higher BP, BMI, or fasting glucose—prioritizing individualized profiles over composite risk categories.
Key Findings
- Nationwide cohort (n=150,830): SGLT2i associated with lower 3-year composite risk vs DPP4i (absolute risk reduction ≈0.38 percentage points; 95% CI 0.16–0.61)
- Heterogeneous treatment effects with weak correlation to overall CVD risk (r=0.287)
- In low CVD-risk stratum (n=107,425), 91% predicted to benefit; higher BP, BMI, and fasting glucose marked likely beneficiaries
Methodological Strengths
- Target trial emulation with active-comparator design (SGLT2i vs DPP4i)
- Machine-learning causal forest to quantify heterogeneous treatment effects at the individual level
Limitations
- Observational design susceptible to residual confounding and selection bias
- Limited generalizability (working-age cohort; 13.3% female); effect size (ARR ~0.38%) is modest at population level
Future Directions: Prospective pragmatic trials validating HTE-guided prescribing, integration of multi-omics and real-time EHR features to refine individual benefit prediction.
AIMS: Evidence is limited as to who benefit the most from sodium-glucose cotransporter-2 inhibitors (SGLT2i), especially among people without elevated cardiovascular disease (CVD) risk. To address this knowledge gap, we investigated the heterogeneity in the effect of SGLT2i across CVD risk profiles. METHODS: Using a target trial emulation framework, we compared SGLT2i versus dipeptidyl peptidase 4 inhibitors (DPP4i) in a nationwide insurer-based database of working-age Japanese citizens in 2015-2023. The primary outcome was a composite of all-cause death, myocardial infarction, stroke, or heart failure over three years. Machine-learning causal forest was applied to assess heterogeneity by predicting individual-level risk reduction in primary outcomes by SGLT2i, and its correlation with CVD risk score. RESULTS: Overall, among 150,830 individuals included in this study (mean age, 54 years; female, 13.3%), SGLT2i was associated with decreased risk of primary outcomes (3-year risk difference, +0.38 [95%CI, 0.16-0.61] percentage points). The causal forest model revealed heterogeneity in the effectiveness of SGLT2i, with estimated benefit correlating weakly with CVD risk score (r=0.287, p<0.001). In particular, among 107,425 individuals with low CVD risk, 97,757 (91.0%) were predicted to benefit from SGLT2i. This subpopulation was characterized as individuals with higher blood pressure, body mass index, and fasting plasma glucose levels even with low CVD risk score. CONCLUSION: The cardioprotective effect of SGLT2i was heterogeneous and more strongly predicted by individual patient characteristics than by overall CVD risk score, highlighting the importance of considering its benefit beyond the conventional risk stratification approach. In this nationwide cohort study which applied machine-learning causal forest to a target trial emulation framework to investigate heterogeneous treatment effects of sodium-glucose cotransporter inhibitors (SGLT2i), a substantial number of individuals were predicted to benefit from SGLT2i. The treatment benefit was more strongly predicted by individual patient characteristics, including blood pressure, body-mass index, and fasting plasma glucose, than by overall CVD risk score, highlighting the importance of considering its benefit beyond the conventional risk stratification approach. Key Findings:The effect of SGLT2i on cardiovascular outcomes was heterogeneous. A substantial number of individuals were predicted to benefit from SGLT2i, and they were likely to have higher blood pressure, body mass index, and high plasma glucose levels.The effectiveness of SGLT2i correlated weakly with overall cardiovascular risk. Individual risk factors, particularly with high blood pressure, high body mass index, and high plasma glucose levels, were more strongly associated with treatment effect.
3. Beyond BMI: The role of diabetes and central obesity in fracture risk-Insights from the UK biobank.
In 446,219 UK Biobank participants, overweight and obesity were associated with lower overall fracture risk versus normal BMI. However, among overweight/obese individuals, greater waist circumference increased fracture risk, and diabetes independently elevated fracture risk across all BMI categories.
Impact: Challenges the simplistic notion of BMI-related protection by demonstrating that central adiposity and diabetes identify higher skeletal risk within overweight/obese populations.
Clinical Implications: Fracture risk assessment in overweight/obese adults should incorporate central adiposity metrics (waist circumference/WHtR) and diabetes status rather than relying on BMI alone.
Key Findings
- Overweight (aHR 0.79, 95% CI 0.76–0.82) and obesity (aHR 0.73, 95% CI 0.70–0.77) associated with lower fracture risk vs normal BMI
- Among overweight/obese, higher waist circumference increased fracture risk (aHR 1.12 overweight; 1.23 obese)
- Diabetes independently increased fracture risk across all BMI categories, amplified by central obesity
Methodological Strengths
- Very large prospective cohort (n=446,219) with multivariable Cox modeling
- Stratified analyses by BMI and central adiposity measures (WC, WHtR), clarifying effect modification
Limitations
- Observational design susceptible to residual confounding and healthy volunteer bias in UK Biobank
- Potential misclassification of fracture events and adiposity measures over time
Future Directions: Validate central adiposity thresholds for fracture risk stratification and test whether targeted interventions (e.g., diabetes control, visceral fat reduction) reduce fractures.
BACKGROUND: A higher body mass index (BMI) is associated with lower fracture risk, yet diabetes, linked to central obesity, increases this risk. This study uses the UK Biobank to investigate the interplay between general and central adiposity, diabetes, and fracture risk, focusing on waist circumference (WC) and waist-to-height ratio (WHtR). METHODS: This prospective cohort study included 446,219 UK Biobank participants. Individuals were categorized by BMI (normal, overweight, obese) and by tertiles of WC and WHtR. Multivariable Cox models were used to evaluate the association between these obesity measures and fracture incidence, with additional analysis stratified by diabetes status. RESULTS: Individuals with overweight or obesity had a reduced risk of fracture compared to those with normal weight (adjusted hazard ratio [aHR] 0.79, 95% confidence interval [CI] 0.76-0.82 for overweight; aHR 0.73, 95% CI 0.70-0.77 for obesity). Higher WC and WHtR were generally associated with a lower risk of fracture; however, a U-shaped pattern was observed. Among individuals with overweight or obesity, higher WC was associated with an increased risk of fracture (aHR 1.12, 95% CI 1.05-1.20 in the overweight group; aHR 1.23, 95% CI 1.12-1.35 in the obesity group). Additionally, diabetes was independently associated with a higher fracture risk across all BMI categories, with the risk further elevated in individuals with central obesity. CONCLUSIONS: Although a higher BMI appears protective, central obesity and diabetes are important contributors to increased fracture risk in individuals with obesity. These findings emphasize that, beyond maintaining a healthy weight, clinicians should assess central obesity and diabetes to better identify those at high fracture risk.